Nachrichten zur Illumina Inc. Aktie

Illumina CEO Thaysen on Nvidia Partnership, Genomics, M&A

Illumina CEO Jacob Thaysen discusses the outlook for genomics and the companys partnership with Nvidia. He speaks with Katherine Greifeld…

Illumina, Inc. (ILMN) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

…

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan

Regeneron invests $119.5M in Truvetas Series C, partnering on 10M-patient genome project. Other news includes funding for Inhibrx, Bioptimus, RhyGaze,…

Illumina stock falls on 2025 outlook miss By Investing.com

Illumina stock falls on 2025 outlook miss…

Kaufalarm bei Illumina: Einsatz von KI beschleunigt Lösungssuche für die personalisierte Medizin!

Illumina Inc. (ILMN) (i.) ist ein globaler Marktführer in der DNA-Sequenzierung und Array-basierten Technologien. Anwendungen finden die Lösungen in der…

Illumina Inc.(ILMN): Die Kooperation mit NVIDIA bietet großes Potenzial für die Genomik und Präzisionsmedizin!

Am 13. Januar 2025 hat Illumina Inc. (i.) eine strategische Zusammenarbeit mit NVIDIA verkündet. Hierbei steht der Einsatz von KI…

This Top ETF Has Generated 1,400% Returns in 20 Years. Heres Why It Can Still Soar Even Higher.

Earning a great return in the stock market doesnt necessarily mean you have to be great at picking individual stocks.…

ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series

Illumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits.…

Illumina Aktie: Kursziel gesenkt

New York (www.aktiencheck.de) - Rating-Update: Vijay Kumar, Analyst von Evercore ISI, stuft die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079,…

Illuminas SWOT analysis: stock faces pricing headwinds amid market leadership By Investing.com

Illuminas SWOT analysis: stock faces pricing headwinds amid market leadership…

Illumina Aktie: Downgrade

New York (www.aktiencheck.de) - Rating-Update: Patrick Donnelly, Analyst der Citigroup, stuft die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

…

MYGN Stock Up on Integration of HRD Platform Into Illuminas TSO 500 v2

Myriad Genetics incorporates its proprietary HRD platform in Illuminas updated TruSight Oncology 500 v2 comprehensive gene panel assay.…

Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)

…

Illumina: Taktgeber in der Genomforschung

Illumina hat sich als Schlüsselspieler in der Genomforschung etabliert und prägt mit seinen Technologien die Möglichkeiten der modernen Medizin.…

Illumina Aktie: Neue Produkte und Wachstumsbeschleunigung in 2025

Little Rock (www.aktiencheck.de) - Illumina-Aktienanalyse von Stephens Inc.: 1. Anpassung des Kursziels und Übergewichtung Stephens Inc. hat das Kursziel für die Aktie…

Illumina coverage resumed at equal weight by Morgan Stanley

…

Illumina: Kursziel verbessert

Milwaukee (www.aktiencheck.de) - Rating-Update: Die Analysten von Robert W. Baird stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

Illumina, Inc. (ILMN) Q3 2024 Earnings Call Transcript

…

ILMN Q3 Earnings Top, 24 Sales View Down, Stock Dips in Aftermarket

Illuminas third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.…

Illumina shares fall 5% as Q4 revenue guidance disappoints By Investing.com

Illumina shares fall 5% as Q4 revenue guidance disappoints…

Illuminas Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?

In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing…

ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?

Reaching a new one-year high, Illumina remains in investors sight owing to its strong strategic execution and positive growth outlook.…

Doppelter Analystensupport: Illumina (ILMN) könnte von drei Hauptthemen profitieren. Leerink sieht 40 % Aufwärtspotenzial.

Die Aktie von Illumina (ILMN) könnte jetzt den Boden nachhaltig verlassen. Es handelt sich um ein Unternehmen im Bereich der Genomik,…

Illumina Aktie: Kurszielanhebung

London (www.aktiencheck.de) - Rating-Update: Barclays stuft die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN) weiterhin mit…

Illumina Aktie: Innovationen treiben Wachstum - RBC Capital bleibt optimistisch!

Toronto (www.aktiencheck.de) - Illumina-Aktienanalyse von RBC Capital Markets: Aktuelle Bewertung RBC Capital bleibt optimistisch in Bezug auf Illumina Inc. (ISIN: US4523271090, WKN:…

Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day

Illumina and Exxon Mobile have been highlighted as Zacks Bull and Bear of the Day.…

Global Gene Panel Market Size To Worth USD 4.46 Billion by 2033 | CAGR of 13.75%

The Global Gene Panel Market Size was Valued at USD 1.23 Billion in 2023 and the Worldwide Gene Panel Market…

Illumina: Trendbruch - Hoffnung auf Doppelboden - Chartanalyse

Düsseldorf (www.aktiencheck.de) - Illumina-Chartanalyse von HSBC Trinkaus & Burkhardt: Die Analysten von HSBC Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse…

UK’s venture capitalists brace for tax rises

Plus, corporate failures hit the cleantech industry and the EU’s top court sides with Illumina after a probe into $8bn…

Top EU court sides with U.S. biotech group Illumina in Grail legal battle By Investing.com

Top EU court sides with U.S. biotech group Illumina in Grail legal battle…

EU top court backs Illumina fight against EU probe into Grail deal By Reuters

EU top court backs Illumina fight against EU probe into Grail deal…

Illumina: Upgrade

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Argus Research stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

The Zacks Analyst Blog Highlights DaVita and Illumina

DaVita and Illumina are included in this Analyst Blog.…

Analyst Report: Illumina Inc

…

ILMNs TSO Comprehensive IVD Test Secures FDA Approval as CDx

Illuminas cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted…

FDA approves Illuminas TruSight Oncology biomarker test

…

Global Cancer Biomarkers Market to Surge from USD 22.78 Billion in 2023 to USD 82.66 Billion by 2033, Achieving a CAGR of 13.76%

According to a research report published by Exactitude Consultancy, Companies covered:Abbott Laboratories Inc. - North America, Agilent Technologies Inc. -…

dpa-AFX ProFeed